06.01.15
SWEDEN: Moberg Pharma AB has acquired Balmex from Chattem, the US Consumer Healthcare Division of Sanofi. The purchase price was $3.9 million, according Moberg Pharma.
Balmex is best known for its diaper rash treatments. An adult line for soothing skin irritations was rolled out by the brand in 2013.
Balmex will be sold through Moberg’s current OTC channel in the US, primarily in chain drugstores, such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart as well as specialty retailers including Toys R’ Us and buybuyBABY.
“Adding Balmex to Moberg’s US portfolio is a great fit within our core area of topical dermatology,” noted said Peter Wolpert, CEO of Moberg Pharma AB. “We are continuously evaluating deal opportunities to further leverage our US sales and marketing infrastructure. This deal contributes immediately to our sales and earnings and to our long-term financial goal of delivering profitable growth and an EBITDA margin of 25% from 2016.”
Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal and Kerasal Nail, topical pain relief cream Jointflex and skin treatment Domeboro, as well as Vanquish and Fergon ingestible remedies.
Balmex is best known for its diaper rash treatments. An adult line for soothing skin irritations was rolled out by the brand in 2013.
Balmex will be sold through Moberg’s current OTC channel in the US, primarily in chain drugstores, such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart as well as specialty retailers including Toys R’ Us and buybuyBABY.
“Adding Balmex to Moberg’s US portfolio is a great fit within our core area of topical dermatology,” noted said Peter Wolpert, CEO of Moberg Pharma AB. “We are continuously evaluating deal opportunities to further leverage our US sales and marketing infrastructure. This deal contributes immediately to our sales and earnings and to our long-term financial goal of delivering profitable growth and an EBITDA margin of 25% from 2016.”
Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal and Kerasal Nail, topical pain relief cream Jointflex and skin treatment Domeboro, as well as Vanquish and Fergon ingestible remedies.